The Lafayette-based company will produce pharmaceutical grade marijuana for patients suffering from cancer, HIV/AIDS, cachexia or wasting syndrome, seizure disorders, epilepsy, spasticity, Chron's disease, muscular distrophy, and multiple sclerosis. Patients will receive the medication in the form of oils, pills, powders, gelatin-based chewables and other non-inhalable forms.

Advanced Biomedics will cultivate medical marijuana for Southern University after the Board of Supervisors voted to approve the vendor at the September 22 meeting.

The Lafayette-based company will produce pharmaceutical grade marijuana for patients suffering from cancer, HIV/AIDS, cachexia or wasting syndrome, seizure disorders, epilepsy, spasticity, Chron's disease, muscular distrophy, and multiple sclerosis. Patients will receive the medication in the form of oils, pills, powders, gelatin-based chewables and other non-inhalable forms.

Under the proposed agreement, the Southern University AgCenter will receive over $6 million over five years. No taxpayer dollars will go towards the marijuana cultivation. Advanced Biomedics will also support research initiates through the center's Southern Institute of Medicinal Plants.

“The research conducted at SIMP will focus on enhancing the knowledge base of plants and their potential of therapeutic effects and medical uses on human health,” said Dr. Janana Snowden, Director of SIMP.

Southern and LSU were granted first right of refusal to become licensed to grow the state's medical marijuana after legislation was passed in the 2016 regular session that outlined how the plant would be dispensed to patients. Both accepted and are the only two licensed entities in the state.

Follow Halen on Twitter: @LikeVanHalen